Le Lézard
Classified in: Health
Subject: FDA

Abbott Announces FDA Clearance for its Alinitytm ci-series Next-generation Diagnostic Systems



ABBOTT PARK, Ill., Oct. 31, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinitytm ci-series instruments for clinical chemistry and immunoassay diagnostics. These innovative testing solutions were designed to help the lab more effectively address modern industry challenges, including aging populations, growing management of chronic diseases and increased access to care, which are driving increases in testing volume.

"Healthcare systems across the United States are under pressure to deliver better care for patients," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Labs and healthcare systems are looking for complete solutions that help them operate more efficiently while contributing to better clinical decision making and helping improve patient outcomes. FDA clearance is a key first step in bringing this important innovation to our U.S. customers as we work to gain approval for the full Alinity portfolio of instruments and assays."

The Alinity ci-series is part of a unified family of personalized solutions that are engineered for flexibility and efficiency. The design is based on insights from thousands of customers, resulting in a number of benefits including:

The "Alinity c" clinical chemistry system, and the "Alinity i" immunoassay system, can operate individually or as an integrated Alinity ci-series unit, allowing for greater productivity in half the footprint of current diagnostics systems. In addition to the instrument clearance, several clinical chemistry and immunoassay tests are now cleared in the U.S. for the system, with a comprehensive menu of tests expected to be available within a year of launch. The Alinity ci-series obtained CE Mark earlier this year and is available in Europe, Middle East, Asia and Latin Americaii.

"Alinity ci was designed using a different approach. We went beyond traditional market research and spent countless hours with our customers, listening to their challenges and observing how they work," said John Frels, Vice President, Immunoassay and Clinical Chemistry Research and Development. "With customer insights as our roadmap, the Alinity ci is engineered to simplify diagnostic testing while ensuring speed, accuracy and performance."

About Alinity
The Alinity portfolio includes clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics, along with Abbott's AlinIQ?a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics. Alinity is helping labs and hospital systems solve some of their most pressing challenges to deliver better patient care with fewer resources. More information is available at abbott.com/alinity.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal. 

i Dependent upon clinical chemistry and immunoassay test mix.
ii Instrument and test availability can vary by geography.

Abbott Logo (PRNewsFoto/Abbott)

 

SOURCE Abbott


These press releases may also interest you

23 oct 2018
Marapharm Ventures Inc. ("Marapharm" or the "Company") wishes to announce that further to its news release on September 26, 2018, the Company has closed over-subscribed on the non-brokered unsecured debenture financing ("Debenture Offering")...

23 oct 2018
CStone Pharmaceuticals ("CStone") today announced that the United States Food and Drug Administration (FDA) has recently granted approval to the company's Investigational New Drug (IND) application for the independently developed recombinant...

23 oct 2018
About Peripheral NeuropathyPeripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical...

23 oct 2018
The global healthcare consulting services market projected to grow at a CAGR of 10.2% during the forecast periodRead the full report: https://www.reportlinker.com/p05598595 The global healthcare consulting services market is expected to reach USD...

23 oct 2018
SAN JOSE, Calif., Oct. 23, 2018 /PRNewswire-PRWeb/ -- Molecular Devices LLC, a leader in protein and cell biology technologies, today announced a new, exciting brand for its recently created biologics solutions business unit. The business unit...

23 oct 2018
BATTESVILLE, Ind., Oct. 23, 2018 /PRNewswire-PRWeb/ -- After extensive review and evaluation, Trinity Guardion's flagship product, the Soteriatm Bed Barrier (also known as the Trinity Guardion® Patient Protection System), was selected by Crothall...




News published on 31 october 2017 at 09:00 and distributed by: